Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 01, 2019 08:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics to Host Conference Call Announcing Second Quarter 2019 Financial Results and Business Updates

CAMBRIDGE, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
June 12, 2019 08:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Announces Appointment of Brian C. DeSchuytner as Senior Vice President of Finance and Product Strategy

Brings Significant Strategic and Operational Experience from Leading Oncology Companies Company Announces Chief Financial Officer Transition CAMBRIDGE, Mass., June 12, 2019 (GLOBE...
June 01, 2019 09:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Presents Interim Phase 1 Data for XMT-1536 at the 2019 American Society of Clinical Oncology Annual Meeting

Encouraging early signs of clinical efficacy Well tolerated with favorable safety profile in heavily pre-treated patient population CAMBRIDGE, Mass., June 01, 2019 (GLOBE NEWSWIRE) -- Mersana...
May 30, 2019 08:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics to Present at the Jefferies 2019 Global Healthcare Conference

CAMBRIDGE, Mass., May 30, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
May 20, 2019 08:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics to Present Interim Phase 1 Data on XMT-1536 at the 2019 American Society of Clinical Oncology Annual Meeting

CAMBRIDGE, Mass., May 20, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
May 09, 2019 06:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Announces First Quarter 2019 Financial Results and Provides Business Updates

Emerging Safety and Tolerability Profile Supports Advancement of Program; Plans for Expansion Cohort Initiation on Track Company Plans to Present Interim Data from the Ongoing XMT-1536 Dose...
May 02, 2019 08:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics to Host Conference Call Announcing First Quarter 2019 Financial Results and Business Updates

CAMBRIDGE, Mass., May 02, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
April 01, 2019 08:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

CAMBRIDGE, Mass., April 01, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
March 25, 2019 08:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Announces Poster and Presentation at the American Association for Cancer Research Annual Meeting 2019

CAMBRIDGE, Mass., March 25, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
March 08, 2019 06:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Business Updates

Company Plans to Report XMT-1536 Dose Escalation Data in the Second Quarter of 2019 Ended 2018 with $70 Million in Cash Further Strengthened Balance Sheet with Gross Proceeds of $98 Million from...